To evaluate the efficacy and safety of Kuntai Capsule for treating premature ovarian failure(POF).Methods:Databases such as Cochrane library，PubMed，Medline，CNKI，VIP，WanFang，and SinoMed were searched for randomized controlled trials(RCT)from inception of the databases to December 2019.The methodological quality was assessed among the included RCTs.The treatment of POF by Kuntai Capsule or hormone was systematically evaluated by RevMan 5.3 software.Results:A total of 8 RCTs with 659 patients were included.Meta-analysis results showed that the total clinical efficacy，serum FSH level，LH level，and E2 level improvement were not statistically significant between Kuntai capsule group and hormone group(P>0.05).The incidence of adverse reactions was significantly lower in Kuntai Capsule groups compared to hormone groups(RR=0.25，95%CI:0.15 to 0.42，P<0.000 01).Conclusion:The clinical efficacy of Kuntai Capsule in the treatment of POF is comparable to that of hormone therapy，and its safety is superior to that of hormone therapy.However，due to the limited quality and quantity of included studies，more high-quality，large-sample and multi-central RCTs are needed to confirm the above conclusion.